Загрузка...
A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis
Denosumab, a fully human monoclonal antibody to RANK ligand [RANK-L]) was approved for the treatment of postmenopausal osteoporosis in June 2010, and is highly effective in reducing the risk of vertebral, nonvertebral, and hip fracture risk. The registration of denosumab was the culmination of the d...
Сохранить в:
| Главный автор: | |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3383499/ https://ncbi.nlm.nih.gov/pubmed/22870485 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X11424220 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|